RecruitingPhase 2NCT06792695

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (CANTOR)

Sponsor

AstraZeneca

Enrollment

120 participants

Start Date

Mar 12, 2025

Study Type

INTERVENTIONAL

Conditions

Metastatic Colorectal Cancer

Summary

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Eligibility

Min Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This study tests new drug combinations for people with advanced colorectal cancer (cancer of the large intestine or rectum) that has spread. It focuses specifically on a subgroup of colorectal cancers with a particular molecular profile called pMMR/MSS, which does not typically respond to standard immunotherapy. **You may be eligible if...** - You are 18 or older with confirmed colorectal cancer that has spread or cannot be surgically removed - You have not previously received chemotherapy for advanced disease - Your cancer has the pMMR/MSS molecular profile - Your overall health status is good (ECOG 0–1) **You may NOT be eligible if...** - Your cancer has spread to the brain or spinal cord - You have serious organ problems that would prevent treatment - Your body weight is under 35 kg Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVolrustomig

Volrustomig will be administered as intravenous (IV) infusion.

DRUGFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)

FOLFIRI will be administered as IV infusion.

DRUGBevacizumab

Bevacizumab will be administered as IV infusion.

Locations(76)

Research Site

Scottsdale, Arizona, United States

Research Site

Los Angeles, California, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Chicago, Illinois, United States

Research Site

Baltimore, Maryland, United States

Research Site

Boston, Massachusetts, United States

Research Site

Rochester, Minnesota, United States

Research Site

Trenton, New Jersey, United States

Research Site

Rochester, New York, United States

Research Site

Cleveland, Ohio, United States

Research Site

Portland, Oregon, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

Nashville, Tennessee, United States

Research Site

Houston, Texas, United States

Research Site

East Melbourne, Australia

Research Site

Wollongong, Australia

Research Site

Woodville South, Australia

Research Site

Victoria, British Columbia, Canada

Research Site

Barrie, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Chengdu, China

Research Site

Harbin, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Wuhan, China

Research Site

Zhengzhou, China

Research Site

Bordeaux, France

Research Site

Marseille, France

Research Site

Montpellier, France

Research Site

Montpellier, France

Research Site

Poitiers, France

Research Site

Saint-Priez En Jarez, France

Research Site

Villejuif, France

Research Site

Berlin, Germany

Research Site

Dresden, Germany

Research Site

Essen, Germany

Research Site

Hamburg, Germany

Research Site

Marburg, Germany

Research Site

Bologna, Italy

Research Site

Castelfranco Veneto, Italy

Research Site

Florence, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Naples, Italy

Research Site

Pavia, Italy

Research Site

Pisa, Italy

Research Site

Roma, Italy

Research Site

Amsterdam, Netherlands

Research Site

Maastricht, Netherlands

Research Site

Zwolle, Netherlands

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Yongin-si, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Santander, Spain

Research Site

Valencia, Spain

Research Site

Kaohsiung City, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Yung Kang City, Taiwan

Research Site

Cambridge, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

Research Site

Metropolitan Borough of Wirral, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06792695

Related Trials

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT061494811 location

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

NCT011741211 location

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT0492922376 locations

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

NCT075597601 location

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649286 locations